p38 MAPK downregulates phosphorylation of Bad in doxorubicin-induced endothelial apoptosis

Biochemical and Biophysical Research Communications

Volumn 347, Issue 3, 2006, Pages 781-790

  Grethe, Simone ^a   Coltella, Nadia ^b   Di Renzo, Maria Flavia ^b   Pörn Ares, M Isabella ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Akt; Bad; Doxorubicin; Endothelial cells; p38 MAPK

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CASPASE 3; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BCL XL; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; CASPASE 3; CASPASES; CELL LINE; DOWN-REGULATION; DOXORUBICIN; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 33746214638     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.06.159     Document Type: Article

References (55)

1. Weiss R.B. The anthracyclines: will we ever find a better doxorubicin?. Semin. Oncol. 19 (1992) 670-686
2. Buzdar A.U., Marcus C., Smith T.L., and Blumenschein G.R. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55 (1985) 2761-2765
3. Kotamraju S., Konorev E.A., Joseph J., and Kalyanaraman B. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J. Biol. Chem. 275 (2000) 33585-33592
4. 2- and p53-dependent pathways. J. Biol. Chem. 279 (2004) 25535-25543
5. Conklin K.A. Coenzyme Q10 for prevention of anthracycline-induced cardiotoxicity. Integr. Cancer Ther. 4 (2005) 110-130
6. Bocci G., Nicolaou K.C., and Kerbel R.S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 62 (2002) 6938-6943
7. Schiffelers R.M., Koning G.A., ten Hagen T.L., Fens M.H., Schraa A.J., Janssen A.P., Kok R.J., Molema G., and Storm G. Anti-tumor efficacy of tumor vasculature targeted liposomal doxorubicin. J. Control. Release 91 (2003) 115-122
8. Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., Longhi R., Allen T.M., Corti A., and Ponzoni M. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 63 (2003) 7400-7409
9. Kalyanaraman B., Joseph J., Kalivendi S., Wang S., Konorev E., and Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol. Cell. Biochem. 234-235 (2002) 119-124
10. Wu S., Ko Y.S., Teng M.S., Ko Y.L., A Hsu L., Hsueh C., Chou Y.Y., Liew C.C., and Lee Y.S. Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J. Mol. Cell. Cardiol. 34 (2002) 1595-1607
11. L. Exp. Cell Res. 298 (2004) 632-642
12. Grethe S., and Pörn-Ares M.I. p38 MAPK mediates inhibition of Bad via PP2A-dependent suppression of the MEK1/2-ERK1/2 survival pathway in TNF-α-induced endothelial apoptosis. Cell. Signal. 18 (2006) 531-540
13. Zhang W., and Liu H.T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 12 (2002) 9-18
14. Guise S., Braguer D., Carles G., Delacourte A., and Briand C. Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells. J. Neurosci. Res. 63 (2001) 257-267
15. Tang D., Wu D., Hirao A., Lahti J.M., Liu L., Mazza B., Kidd V.J., Mak T.W., and Ingram A.J. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J. Biol. Chem. 277 (2002) 12710-12717
16. Yeh P.Y., Chuang S.E., Yeh K.H., Song Y.C., Chang L.L., and Cheng A.L. Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. Oncogene 23 (2004) 3580-3588
17. Stephens L., Anderson K., Stokoe D., Erdjument-Bromage H., Painter G.F., Holmes A.B., Gaffney P.R., Reese C.B., McCormick F., Tempst P., Coadwell J., and Hawkins P.T. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279 (1998) 710-714
18. Toker A., and Newton A.C. Akt/Protein Kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J. Biol. Chem. 275 (2000) 8271-8274
19. Persad S., Attwell S., Gray V., Mawji N., Deng J.T., Leung D., Yan J., Sanghera J., Walsh M.P., and Dedhar S. Regulation of Protein Kinase B/Akt-Serine 473 phosphorylation by integrin-linked kinase. J. Biol. Chem. 276 (2001) 27462-27469
20. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., Frisch S., and Reed J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
21. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., and Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
22. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., and Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999) 857-868
23. Pap M., and Cooper G.M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J. Biol. Chem. 273 (1998) 19929-19932
24. Kane L.P., Shapiro V.S., Stokoe D., and Weiss A. Induction of NFκB by the Akt/PKB kinase. Curr. Biol. 9 (1999) 601-604
25. Secchiero P., Gorelli A., Carnevale E., Milani D., Pandolfi A., Zella D., and Zauli G. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107 (2003) 2250-2256
26. Takeuchi K., and Ito F. Suppression of adriamycin-induced apoptosis by sustained activation of the phosphatidylinositol-3′-OH kinase-Akt pathway. J. Biol. Chem. 279 (2004) 892-900
27. Downward J. How BAD phosphorylation is good for survival. Nat. Cell Biol. 1 (1999) E33-E35
28. Yang E., Zha J., Jockel J., Boise L.H., Thompson C.B., and Korsmeyer S.J. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80 (1995) 285-291
29. 155. J. Biol. Chem. 275 (2000) 25046-25051
30. Harada H., Becknell B., Wilm M., Mann M., Huang L.J., Taylor S.S., Scott J.D., and Korsmeyer S.J. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol. Cell 3 (1999) 413-422
31. Shimamura A., Ballif B.A., Richards S.A., and Blenis J. Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr. Biol. 10 (2000) 127-135
32. Schürmann A., Mooney A.F., Sanders L.C., Sells M.A., Wang H.G., Reed J.C., and Bokoch G.M. p21-activated kinase 1 phosphorylates the death agonist Bad and protects cells from apoptosis. Mol. Cell Biol. 20 (2000) 453-461
33. Harada H., Andersen J.S., Mann M., Terada N., and Korsmeyer S.J. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. USA 98 (2001) 9666-9670
34. Edgell C.J., McDonald C.C., and Graham J.B. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc. Natl. Acad. Sci. USA 80 (1983) 3734-3737
35. Lorenzo E., Ruiz-Ruiz C., Quesada A.J., Hernandez G., Rodriguez A., Lopez-Rivas A., and Redondo J.M. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J. Biol. Chem. 277 (2002) 10883-10892
36. Follenzi A., Ailles L.E., Bakovic S., Geuna M., and Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25 (2000) 217-222
37. Han J., Lee J.D., Bibbs L., and Ulevitch R.J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265 (1994) 808-811
38. Bardella C., Costa B., Maggiora P., Patane S., Olivero M., Ranzani G.N., De Bortoli M., Comoglio P.M., and Di Renzo M.F. Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression. Cancer Res. 64 (2004) 5154-5161
39. Gianni L., Zweier J.L., Levy A., and Myers C.E. Characterization of the cycle of iron-mediated electron transfer from Adriamycin to molecular oxygen. J. Biol. Chem. 260 (1985) 6820-6826
40. Vasquez-Vivar J., Martasek P., Hogg N., Masters B.S., Pritchard Jr. K.A., and Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 36 (1997) 11293-11297
41. Hashimoto S., Gon Y., Matsumoto K., Takeshita I., and Horie T. N-acetylcysteine attenuates TNF-alpha-induced p38 MAP kinase activation and p38 MAP kinase-mediated IL-8 production by human pulmonary vascular endothelial cells. Br. J. Pharmacol. 132 (2001) 270-276
42. Gum R.J., McLaughlin M.M., Kumar S., Wang Z., Bower M.J., Lee J.C., Adams J.L., Livi G.P., Goldsmith E.J., and Young P.R. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB203580, by alteration of one or more amino acids within the ATP binding pocket. J. Biol. Chem. 273 (1998) 15605-15610
43. 2-terminal kinase to induce apoptosis. Mol. Biol. Cell 16 (2005) 3821-3831
44. Breitschopf K., Haendeler J., Malchow P., Zeiher A.M., and Dimmeler S. Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol. Cell. Biol. 20 (2000) 1886-1896
45. Sanchez-Prieto R., Rojas J.M., Taya Y., and Gutkind J.S. A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res. 60 (2000) 2464-2472
46. Kang Y.J., Zhou Z.X., Wang G.W., Buridi A., and Klein J.B. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J. Biol. Chem. 275 (2000) 13690-13698
47. Poizat C., Puri P.L., Bai Y., and Kedes L. Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac cells. Mol. Cell. Biol. 25 (2005) 2673-2687
48. Liem A.A., Appleyard M.V., O'Neill M.A., Hupp T.R., Chamberlain M.P., and Thompson A.M. Doxorubicin and vinorelbine act independently via p53 expression and p38 activation respectively in breast cancer cell lines. Br. J. Cancer 88 (2003) 1281-1284
49. Zhao Y., You H., Yang Y., Wei L., Zhang X., Yao L., Fan D., and Yu Q. Distinctive regulation and function of PI 3K/Akt and MAPKs in doxorubicin-induced apoptosis of human lung adenocarcinoma cells. J. Cell. Biochem. 91 (2004) 621-632
50. Negoro S., Oh H., Tone E., Kunisada K., Fujio Y., Walsh K., Kishimoto T., and Yamauchi-Takihara K. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation 103 (2001) 555-561
51. Kunisada K., Tone E., Negoro S., Nakaoka Y., Oshima Y., Osugi T., Funamoto M., Izumi M., Fujio Y., Hirota H., and Yamauchi-Takihara K. Bcl-xL reduces doxorubicin-induced myocardial damage but fails to control cardiac gene downregulation. Cardiovasc. Res. 53 (2002) 936-943
52. Simoes-Wüst A.P., Schürpf T., Hall J., Stahel R.A., and Zangemeister-Wittke U. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res. Treat. 76 (2002) 157-166
53. Gratton J.P., Morales-Ruiz M., Kureishi Y., Fulton D., Walsh K., and Sessa W.C. Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells. J. Biol. Chem. 276 (2001) 30359-30365
54. Yuan Z., Feldman R.I., Sussman G.E., Coppola D., Nicosia S.V., and Cheng J.Q. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J. Biol. Chem. 278 (2003) 23432-23440
55. Chiang C.W., Kanies C., Kim K.W., Fang W.B., Parkhurst C., Xie M., Henry T., and Yang E. Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis. Mol. Cell. Biol. 23 (2003) 6350-6362